top of page

Allurion reveals data showing lean mass gains in patients experiencing 14% weight loss

Allurion Technologies has announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at four months on the Allurion Program. Vital signs and physical activity were tracked in real-time with the Allurion App, Connected Scale, and Health Tracker, and follow-up was provided through the AI-powered Allurion Virtual Care Suite.

In the study, 571 patients across three obesity centres treated with the Allurion Program reduced their weight on average by 13.9kg from 97.9kg to 84.0kg in just four months. Over that same period, lean mass, which includes muscle mass, increased by 2.8kg on average from 49.8kg to 52.6kg.

Higher activity patients, walking more than 8,000 daily steps on average, achieved higher weight loss (15.6kg on average, from 97.7kg to 82.1kg) and gained more lean mass (increased by 2.8kg on average from 50.9kg to 53.7kg) than their lower activity counterparts who achieved a weight loss of 13.6kg on average, from 98.2kg to 84.6kg, and whose lean mass increased by 1.8kg on average, from 49.5 to 51.3kg.

All patients experienced significant reductions in body fat percentage, decreasing from 32.7% to 27.9% in just 4 months.

Previous studies evaluating body composition changes in patients treated with GLP-1s have demonstrated that lean body mass losses are common, ranging from 3-11% lean mass reductions after around a year of treatment. Importantly, these studies did not incorporate any real-time monitoring of body composition or personalized approaches to promote lean mass preservation or muscle mass gain.

“Historically, weight loss has come at the expense of lean muscle mass, the maintenance of which is critical to overall health. These results demonstrate just the opposite, providing evidence that it is possible to lose significant amounts of weight while maintaining, and even increasing, lean body mass,” said Dr Shantanu Gaur, Founder and CEO of Allurion. “We believe that this data underscores the impact of real-time monitoring of body composition and personalized recommendations through our AI-powered Virtual Care Suite. In fact, we believe that using Allurion’s AI platform with other modalities - including GLP-1s, where muscle mass loss is a significant risk - may be a promising path forward.”


bottom of page